This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk’s and Eli Lilly’s Weight Loss Treatments
The Motley FoolTerns has a modest market cap of less than $800 million, and its possible upside could be massive.
Terns has a modest market cap of less than $800 million, and its possible upside could be massive.